These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23095928)

  • 1. Are central institutional review boards the solution? The National Heart, Lung, and Blood Institute Working Group's report on optimizing the IRB process.
    Mascette AM; Bernard GR; Dimichele D; Goldner JA; Harrington R; Harris PA; Leeds HS; Pearson TA; Ramsey B; Wagner TH
    Acad Med; 2012 Dec; 87(12):1710-4. PubMed ID: 23095928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transitioning to the National Institutes of Health single institutional review board model: Piloting the use of the Streamlined, Multi-site, Accelerated Resources for Trials IRB Reliance.
    Vardeny O; Hernandez AF; Cohen LW; Franklin A; Baqai M; Palmer S; Bierer BE; Cobb N
    Clin Trials; 2019 Jun; 16(3):290-296. PubMed ID: 30866676
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implementing a Central IRB Model in a Multicenter Research Network.
    Burr JS; Johnson AR; Vasenina V; Bisping S; Coleman RW; Botkin JR; Dean JM
    Ethics Hum Res; 2019 May; 41(3):23-28. PubMed ID: 31108575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policies and management of conflicts of interest within medical research institutional review boards: results of a national study.
    Vogeli C; Koski G; Campbell EG
    Acad Med; 2009 Apr; 84(4):488-94. PubMed ID: 19318786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Members of the same club": challenges and decisions faced by US IRBs in identifying and managing conflicts of interest.
    Klitzman R
    PLoS One; 2011; 6(7):e22796. PubMed ID: 21829516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Operational Characteristics of Institutional Review Boards (IRBs) in the United States.
    Nesom GL; Petrof I; Moore TM
    AJOB Empir Bioeth; 2019; 10(4):276-286. PubMed ID: 31618119
    [No Abstract]   [Full Text] [Related]  

  • 8. Is your ethics committee efficient? Using "IRB Metrics" as a self-assessment tool for continuous improvement at the Faculty of Tropical Medicine, Mahidol University, Thailand.
    Adams P; Kaewkungwal J; Limphattharacharoen C; Prakobtham S; Pengsaa K; Khusmith S
    PLoS One; 2014; 9(11):e113356. PubMed ID: 25406085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central institutional review board review for an academic trial network.
    Kaufmann P; O'Rourke PP
    Acad Med; 2015 Mar; 90(3):321-3. PubMed ID: 25406606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burdens on research imposed by institutional review boards: the state of the evidence and its implications for regulatory reform.
    Silberman G; Kahn KL
    Milbank Q; 2011 Dec; 89(4):599-627. PubMed ID: 22188349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meeting the Challenge: The National Cancer Institute's Central Institutional Review Board for Multi-Site Research.
    Massett HA; Hampp SL; Goldberg JL; Mooney M; Parreco LK; Minasian L; Montello M; Mishkin GE; Davis C; Abrams JS
    J Clin Oncol; 2018 Mar; 36(8):819-824. PubMed ID: 29384720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles, challenges and institutionalization of institutional review boards.
    Oyibo WA; Krugher M; Fagbenro-Beyioku AF
    Nig Q J Hosp Med; 2008; 18(2):115-9. PubMed ID: 19068565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring IRB Regulatory Compliance: Development, Testing, and Use of the National Cancer Institute StART Tool.
    Rooney L; Covington L; Dedier A; Samuel B
    J Empir Res Hum Res Ethics; 2019 Apr; 14(2):95-106. PubMed ID: 30866722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Costs and benefits of the national cancer institute central institutional review board.
    Wagner TH; Murray C; Goldberg J; Adler JM; Abrams J
    J Clin Oncol; 2010 Feb; 28(4):662-6. PubMed ID: 19841324
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should society allow research ethics boards to be run as for-profit enterprises?
    Emanuel EJ; Lemmens T; Elliot C
    PLoS Med; 2006 Jul; 3(7):e309. PubMed ID: 16848618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Institutional Review Boards: Purpose and Challenges.
    Grady C
    Chest; 2015 Nov; 148(5):1148-1155. PubMed ID: 26042632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding institutional review boards: practical guidance to the IRB review process.
    Pech C; Cob N; Cejka JT
    Nutr Clin Pract; 2007 Dec; 22(6):618-28. PubMed ID: 18042949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "We measure what we can measure": Struggles in defining and evaluating institutional review board quality.
    Lynch HF; Eriksen W; Clapp JT
    Soc Sci Med; 2022 Jan; 292():114614. PubMed ID: 34861569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. When IRBs Say No to Participating in Research about Single IRBs.
    Klitzman R; Appelbaum PS; Murray A; Pivovarova E; Stiles DF; Lidz CW
    Ethics Hum Res; 2020 Jan; 42(1):36-40. PubMed ID: 31967411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variability in the costs of institutional review board oversight.
    Byrne MM; Speckman J; Getz K; Sugarman J
    Acad Med; 2006 Aug; 81(8):708-12. PubMed ID: 16868423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.